Abstract 269MO
Background
Women with metastatic breast cancer (mBC) experience breast cancer- and treatment-related side effects that impair activities of daily living. Evidence for exercise effects on rarely addressed problems such as sexual health or body image is lacking to date, especially for patients with advanced disease. Thus, we investigated the effects of a structured exercise intervention in women with mBC on sexual health and breast cancer-specific symptoms.
Methods
The multinational EFFECT study, including 355 women (and 2 men) with mBC from 5 European countries and Australia, randomly assigned participants to either usual care (UC) or a 9-month supervised exercise program (EX) combining aerobic, resistance, and balance exercises. All participants received general exercise advice and an activity tracker. Breast cancer-specific symptoms (EORTC QLQ-BR45) were assessed at baseline, 3, 6 (primary timepoint), and 9 months. Intervention effects were analyzed on an intent-to-treat basis with mixed models for repeated measures, adjusted for baseline values of the outcome variable and stratification factors (line of treatment and study center).
Results
Female participants had a mean ± SD age of 55.4 ± 11.1 years, mostly received 1st/second-line treatment at study enrollment (74.8%) and had bone metastases (67.5%). At baseline, sexual functioning (17.1±21.2) was low, associated with older age and depressive symptoms. Almost half of sexually active women reported little sexual enjoyment, 26% of all participants reported moderate-to-severe endocrine sexual symptoms and 24% a poor body image. Exercise improved sexual functioning (effect size (ES)=0.28, p=.0031) and endocrine sexual symptoms (ES=0.25, p=.0026) at 6-month. The exercise effect on sexual functioning was sustained at 9-month (ES=0.23, p=.020).
Conclusions
Women with mBC are likely to experience sexual problems and may have an impaired body image. Exercise can help improve sexual health in these patients. Further research should determine the optimal role of exercise in addressing symptom burden, possibly in conjunction with additional support.
Clinical trial identification
NCT04120298.
Legal entity responsible for the study
PREFERABLE consortium.
Funding
European Union’s Horizon 2020 research and innovation program (No 825677) and the National Health and Medical Research Council of Australia (2018/GNT1170698).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
LBA1 - Denosumab added to 2 different nab-paclitaxel regimens as neoadjuvant therapy in patients with primary breast cancer: Time to event analysis from the GeparX 2 × 2 randomized clinical trial
Presenter: Sibylle Loibl
Session: Mini Oral session 2
Resources:
Abstract
Slides
Webcast
110MO - Statin use and early breast cancer survival: A Danish population-based cohort study using an emulated target trial approach
Presenter: Sixten Harborg
Session: Mini Oral session 2
Resources:
Abstract
Slides
Webcast
111MO - Tailored dose-dense versus standard adjuvant chemotherapy for high-risk early breast cancer: Efficacy outcomes and key subgroups after 10 years of follow-up in the randomized phase III PANTHER trial
Presenter: Theodoros Foukakis
Session: Mini Oral session 2
Resources:
Abstract
Slides
Webcast
Invited Discussant LBA1, 110MO and 111MO
Presenter: Elzbieta Senkus-Konefka
Session: Mini Oral session 2
Resources:
Slides
Webcast
268MO - Safety of vaginal estrogen therapy after early-stage breast cancer: A nationwide population-based target trial emulation
Presenter: Elise Dumas
Session: Mini Oral session 2
Resources:
Abstract
Slides
Webcast
270MO - An international update of the EORTC questionnaire for assessing quality of life in breast cancer patients: Results of the validation study phase IV EORTC QLQ-BR42
Presenter: Vesna Bjelic-Radisic
Session: Mini Oral session 2
Resources:
Abstract
Slides
Webcast
Invited Discussant 268MO, 269MO and 270MO
Presenter: Matteo Lambertini
Session: Mini Oral session 2
Resources:
Slides
Webcast
112MO - Neoadjuvant study of 12 months of abemaciclib plus letrozole vs chemotherapy in HR+/HER2– highly proliferative (Ki67=20%) breast cancer: CARABELA (GEICAM/2019-01) trial
Presenter: Miguel Martin Jimenez
Session: Mini Oral session 2
Resources:
Abstract
Slides
Webcast
184MO - First-in-human phase I/IIa study of the first-in-class, next-generation CDK4-selective inhibitor PF-07220060 in combination with endocrine therapy (ET) in patients (pts) with HR+/HER2- metastatic breast cancer (mBC) who progressed on prior CDK4/6 inhibitors (CDK4/6i): Safety and efficacy update
Presenter: Timothy Yap
Session: Mini Oral session 2
Resources:
Abstract
Slides
Webcast
113MO - NATALEE update: Safety and treatment (tx) duration of ribociclib (RIB) + nonsteroidal aromatase inhibitor (NSAI) in patients (pts) with HR+/HER2- early breast cancer (EBC)
Presenter: Carlos Barrios
Session: Mini Oral session 2
Resources:
Abstract
Slides
Webcast